Cure My Disease

Don't miss your cure!

 Log in / Sign up

Muscle-Saving supplement may shield seniors from Weight-Loss drug side effect

NCT ID NCT07760948

Not yet recruiting Disease control Sponsor: Vanderbilt University Medical Center Source: ClinicalTrials.gov ↗

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This trial tests whether a daily supplement of calcium-HMB plus vitamin D3 can help adults aged 65 to 85 with type 2 diabetes keep their muscle mass and metabolism while starting semaglutide, a common weight-loss and diabetes medication. Participants take the supplement or a placebo for about 6 months. Researchers measure changes in muscle mass, strength, physical function, and resting metabolism to see if the supplement counters the muscle loss that can accompany semaglutide use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
calcium-HMB (beta-hydroxy-beta-methylbutyrate) plus vitamin D3
What this could lead to
If effective, this supplement could help older adults on semaglutide lose fat while keeping muscle and metabolic health, improving physical function and quality of life.
What could go wrong
This is a small, early-stage trial. The supplement may not prevent muscle loss, and results may not apply to all older adults. Side effects are possible but generally mild.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MUSCLE LOSS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

muscular atrophy Obesity obesity disorder Sarcopenia type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MUSCLE LOSS OBESITY OLDER ADULTS SARCOPENIA TYPE 2 DIABETES MELLITUS (T2DM)

Contacts and locations

Locations

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.